Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Imagine Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The research collaboration will leverage Imagine Pharma’s Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) and LyGenesis’ allogeneic cell therapy platform to develop therapies for type 1 diabetes.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 12, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Imagine Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : AGEX-VASC1
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Recipient : AgeX Therapeutics
Deal Size : Undisclosed
Deal Type : Termination
AgeX Therapeutics and LyGenesis Terminate Merger Negotiations
Details : AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.
Brand Name : AGEX-VASC1
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 23, 2021
Lead Product(s) : AGEX-VASC1
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Recipient : AgeX Therapeutics
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : LYG-LIV0001
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : AgeX Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement
Details : LYG-LIV0001 is a regenerative mobile remedy comprising allogeneic hepatocytes suspended in a buffered cell preservation resolution which are transplanted into periduodenal lymph nodes.
Brand Name : LYG-LIV0001
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 02, 2021
Lead Product(s) : LYG-LIV0001
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : AgeX Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : LYG-LIV0001
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Juvenescence
Deal Size : $11.0 million
Deal Type : Financing
Details : Proceeds will be used to fund LyGenesis’s Phase 2a clinical trial with a first patient in targeted for early 2021, also to push forward on their other cell therapies using lymph nodes as bioreactors to regrow functioning organs.
Brand Name : LYG-LIV0001
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 30, 2020
Lead Product(s) : LYG-LIV0001
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Juvenescence
Deal Size : $11.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?